dry eye

Global biotechnology company, Shire, has submitted a marketing authorisation application (MAA) for its dry eye treatment, liftegrast, which, if approved, would represent the first and only LFA-1 antagonist drug to treat the disease in Europe. Read more


Allergan, a global pharmaceutical company, has completed the acquisition of Oculeve Read more


Novozymes Biopharma, part of Novozymes A/S, announced that an ophthalmic solution made using its recombinant human albumin has been approved for Phase I/II development by the FDA. Read more